BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 37098238)

  • 21. Development and validation of a nomogram for predicting survival in intermediate- and high-risk neuroblastoma of the Children's Oncology Group risk stratification.
    Feng L; Kan Y; Wang W; Wang C; Zhang H; Xie P; Yang J
    J Cancer Res Clin Oncol; 2023 Dec; 149(18):16377-16390. PubMed ID: 37702807
    [TBL] [Abstract][Full Text] [Related]  

  • 22.
    Bhardwaj N; Rohilla M; Trehan A; Bansal D; Kakkar N; Srinivasan R
    J Clin Pathol; 2023 Sep; 76(9):599-605. PubMed ID: 35414524
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management and outcome of stage 3 neuroblastoma.
    Modak S; Kushner BH; LaQuaglia MP; Kramer K; Cheung NK
    Eur J Cancer; 2009 Jan; 45(1):90-8. PubMed ID: 18996003
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a Children's Cancer Group study.
    Matthay KK; Perez C; Seeger RC; Brodeur GM; Shimada H; Atkinson JB; Black CT; Gerbing R; Haase GM; Stram DO; Swift P; Lukens JN
    J Clin Oncol; 1998 Apr; 16(4):1256-64. PubMed ID: 9552023
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Association of heterogeneous MYCN amplification with clinical features, biological characteristics and outcomes in neuroblastoma: A report from the Children's Oncology Group.
    Campbell K; Naranjo A; Hibbitts E; Gastier-Foster JM; Bagatell R; Irwin MS; Shimada H; Hogarty M; Park JR; DuBois SG
    Eur J Cancer; 2020 Jul; 133():112-119. PubMed ID: 32492633
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MYCN RNA levels determined by quantitative in situ hybridization is better than MYCN gene dosages in predicting the prognosis of neuroblastoma patients.
    Chang HH; Tseng YF; Lu MY; Yang YL; Chou SW; Lin DT; Lin KH; Jou ST; Hsu WM; Jeng YM
    Mod Pathol; 2020 Apr; 33(4):531-540. PubMed ID: 31695155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Does MYCN amplification manifested as homogeneously staining regions at diagnosis predict a worse outcome in children with neuroblastoma? A Children's Oncology Group study.
    Moreau LA; McGrady P; London WB; Shimada H; Cohn SL; Maris JM; Diller L; Look AT; George RE
    Clin Cancer Res; 2006 Oct; 12(19):5693-7. PubMed ID: 17020972
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age, Diagnostic Category, Tumor Grade, and Mitosis-Karyorrhexis Index Are Independently Prognostic in Neuroblastoma: An INRG Project.
    Sokol E; Desai AV; Applebaum MA; Valteau-Couanet D; Park JR; Pearson ADJ; Schleiermacher G; Irwin MS; Hogarty M; Naranjo A; Volchenboum S; Cohn SL; London WB
    J Clin Oncol; 2020 Jun; 38(17):1906-1918. PubMed ID: 32315273
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Complete surgical resection improves outcome in INRG high-risk patients with localized neuroblastoma older than 18 months.
    Fischer J; Pohl A; Volland R; Hero B; Dübbers M; Cernaianu G; Berthold F; von Schweinitz D; Simon T
    BMC Cancer; 2017 Aug; 17(1):520. PubMed ID: 28778185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Long-term follow-up of neuroblastoma in children less than 18 months of age].
    Zhao J; Pan C; Xu M; Zhou M; Gao YJ; Hu WT; Tang JY
    Zhonghua Er Ke Za Zhi; 2017 Oct; 55(10):754-759. PubMed ID: 29050113
    [No Abstract]   [Full Text] [Related]  

  • 31. Metastatic neuroblastoma in infants: are survival rates excellent only within the stringent framework of clinical trials?
    Di Cataldo A; Agodi A; Balaguer J; Garaventa A; Barchitta M; Segura V; Bianchi M; Castel V; Castellano A; Cesaro S; Couselo JM; Cruz O; D'Angelo P; De Bernardi B; Donat J; de Andoin NG; Hernandez MI; La Spina M; Lillo M; Lopez-Almaraz R; Luksch R; Mastrangelo S; Mateos E; Molina J; Moscheo C; Mura R; Porta F; Russo G; Tondo A; Torrent M; Vetrella S; Villegas JA; Viscardi E; Zanazzo GA; Cañete A
    Clin Transl Oncol; 2017 Jan; 19(1):76-83. PubMed ID: 27041689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biologic factors determine prognosis in infants with stage IV neuroblastoma: A prospective Children's Cancer Group study.
    Schmidt ML; Lukens JN; Seeger RC; Brodeur GM; Shimada H; Gerbing RB; Stram DO; Perez C; Haase GM; Matthay KK
    J Clin Oncol; 2000 Mar; 18(6):1260-8. PubMed ID: 10715296
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children's Oncology Group Study ANBL0531.
    Twist CJ; Naranjo A; Schmidt ML; Tenney SC; Cohn SL; Meany HJ; Mattei P; Adkins ES; Shimada H; London WB; Park JR; Matthay KK; Maris JM
    J Clin Oncol; 2019 Jan; 37(2):115-124. PubMed ID: 30444686
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nucleolin expression has prognostic value in neuroblastoma patients.
    Cangelosi D; Brignole C; Bensa V; Tamma R; Malaguti F; Carlini B; Giusto E; Calarco E; Perri P; Ribatti D; Fonseca NA; Moreira JN; Eva A; Amoroso L; Conte M; Garaventa A; Sementa AR; Corrias MV; Ponzoni M; Pastorino F
    EBioMedicine; 2022 Nov; 85():104300. PubMed ID: 36209521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic value of the stage 4S metastatic pattern and tumor biology in patients with metastatic neuroblastoma diagnosed between birth and 18 months of age.
    Taggart DR; London WB; Schmidt ML; DuBois SG; Monclair TF; Nakagawara A; De Bernardi B; Ambros PF; Pearson AD; Cohn SL; Matthay KK
    J Clin Oncol; 2011 Nov; 29(33):4358-64. PubMed ID: 21969516
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Neuroblastoma in older children, adolescents and young adults: a report from the International Neuroblastoma Risk Group project.
    Mossé YP; Deyell RJ; Berthold F; Nagakawara A; Ambros PF; Monclair T; Cohn SL; Pearson AD; London WB; Matthay KK
    Pediatr Blood Cancer; 2014 Apr; 61(4):627-35. PubMed ID: 24038992
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chromosome band 11q23 deletion predicts poor prognosis in bone marrow metastatic neuroblastoma patients without MYCN amplification.
    Yue ZX; Xing TY; Gao C; Liu SG; Zhao W; Zhao Q; Wang XS; Jin M; Ma XL
    Cancer Commun (Lond); 2019 Nov; 39(1):68. PubMed ID: 31685009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of the relationship between MYCN gene and serum NSE and urinary VMA levels and neuroblastoma pathological features and prognosis.
    Zhang H; He X; Miao Q; Li L; Song J; Jiang X
    Cell Mol Biol (Noisy-le-grand); 2024 Apr; 70(4):134-139. PubMed ID: 38678619
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Natural history and biology of stage A neuroblastoma: a Pediatric Oncology Group Study.
    Alvarado CS; London WB; Look AT; Brodeur GM; Altmiller DH; Thorner PS; Joshi VV; Rowe ST; Nash MB; Smith EI; Castleberry RP; Cohn SL
    J Pediatr Hematol Oncol; 2000; 22(3):197-205. PubMed ID: 10864050
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical and molecular characterization of patients with stage 4(M) neuroblastoma aged less than 18 months without MYCN amplification.
    Berthold F; Rosswog C; Christiansen H; Frühwald M; Hemstedt N; Klingebiel T; Fröhlich B; Schilling FH; Schmid I; Simon T; Hero B; Fischer M; Ernst A
    Pediatr Blood Cancer; 2021 Aug; 68(8):e29038. PubMed ID: 33826231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.